7th World Symposium on Pulmonary Hypertension
The 7th World Symposium on Pulmonary Hypertension (WSPH), held in 2018 in Nice, France, was a significant global event focused on pulmonary hypertension (PH). This symposium brought together leading experts in the field to review and update the classification, diagnosis, and treatment of pulmonary hypertension. The WSPH is known for setting international standards and guidelines for PH management, providing the latest evidence-based practices for healthcare professionals.
Key Highlights of the 7th WSPH:
Updated PH Classification:
The symposium introduced refinements to the clinical classification of PH, including lowering the mean pulmonary arterial pressure (mPAP) threshold for diagnosing PH from 25 mmHg to 20 mmHg.
Updates were made to the classification of different PH groups, focusing on the underlying causes of PH such as left heart disease (Group 2 PH), lung diseases (Group 3 PH), and chronic thromboembolic pulmonary hypertension (CTEPH).
Diagnosis and Risk Stratification:
The symposium highlighted new approaches for better risk assessment and stratification of PH patients, particularly with regard to prognosis and survival.
Advances in non-invasive imaging techniques and hemodynamic evaluation were emphasized to improve the accuracy of PH diagnosis.
Treatment Recommendations:
The WSPH provided updated guidelines on the use of targeted therapies for pulmonary arterial hypertension (PAH), focusing on the combination of drugs targeting different pathways such as endothelin receptor antagonists, phosphodiesterase inhibitors, and prostacyclin analogs.
New insights were shared on the management of PH associated with left heart disease and chronic lung diseases.
Right Ventricular Function:
A major focus was on the right ventricle's role in PH, stressing the importance of right ventricular function in determining the disease's prognosis and response to treatment.
Future Directions:
The symposium encouraged further research into the genetic and molecular mechanisms of PH, the development of novel therapies, and the need for personalized treatment approaches.
More info : cardiology.pencis.com
Contact : cardiology@pencis.com
#WSPH7
#PulmonaryHypertension
#PHResearch
#PAH
#RightHeartFailure
#Cardiology
#LungHealth
#HeartFailure
#PHGuidelines
#PHUpdates
#CTEPH
#MedicalSymposium
#PHCare
#MedicalGuidelines
